Several clinical trials have shown that EGFR-TKIs (gefitinib, erlotinib, afatinib) produce higher response rates, longer progression-free survival, and are less toxic than platinum-based chemotherapy amongst EGFRmut+ NSCLC patients [5–9]. Here, EGFR is linked to non-small cell lung carcinoma.